Literature DB >> 31420089

Medication Treatment of Opioid Use Disorder.

James Bell1, John Strang2.   

Abstract

Opioid use disorder (OUD) is a chronic, relapsing condition, often associated with legal, interpersonal, and employment problems. Medications demonstrated to be effective for OUD are methadone (a full opioid agonist), buprenorphine (a partial agonist), and naltrexone (an opioid antagonist). Methadone and buprenorphine act by suppressing opioid withdrawal symptoms and attenuating the effects of other opioids. Naltrexone blocks the effects of opioid agonists. Oral methadone has the strongest evidence for effectiveness. Longer duration of treatment allows restoration of social connections and is associated with better outcomes. Treatments for OUD may be limited by poor adherence to treatment recommendations and by high rates of relapse and increased risk of overdose after leaving treatment. Treatment with methadone and buprenorphine has the additional risk of diversion and misuse of medication. New depot and implant formulations of buprenorphine and naltrexone have been developed to address issues of safety and problems of poor treatment adherence. For people with OUD who do not respond to these treatments, there is accumulating evidence for supervised injectable opioid treatment (prescribing pharmaceutical heroin). Another medication mode of minimizing risk of overdose is take-home naloxone. Naloxone is an opioid antagonist used to reverse opioid overdose, and take-home naloxone programs aim to prevent fatal overdose. All medication-assisted treatment is limited by lack of access and by stigma. In seeking to stem the rising toll from OUD, expanding access to approved treatment such as methadone, for which there remains the best evidence of efficacy, may be the most useful approach.
Copyright © 2019 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Buprenorphine; Heroin; Methadone; Naloxone; Naltrexone; Opioid use disorder

Year:  2019        PMID: 31420089     DOI: 10.1016/j.biopsych.2019.06.020

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  37 in total

1.  Effects of 5-HT2A receptor stimulation on economic demand for fentanyl after intermittent and continuous access self-administration in male rats.

Authors:  David Alexander Martin; Utsav Gyawali; Donna J Calu
Journal:  Addict Biol       Date:  2020-05-26       Impact factor: 4.280

2.  Exploring Culturally Based Treatment Options for Opioid Use Disorders Among American Indian and Alaska Native Adults in California.

Authors:  Ingrid Zeledon; Victoria Telles; Daniel Dickerson; Carrie Johnson; Kurt Schweigman; Amy West; Claradina Soto
Journal:  J Stud Alcohol Drugs       Date:  2022-07       Impact factor: 3.346

3.  Role of Peer Coaches in Digital Interventions for MOUD Initiation and Maintenance.

Authors:  Renee Garett; Sean D Young
Journal:  Community Ment Health J       Date:  2022-08-01

4.  Confronting the opioid crisis with basic research in neuropharmacology.

Authors:  Michael H Baumann; Gavril W Pasternak; Sidney S Negus
Journal:  Neuropharmacology       Date:  2020-01-17       Impact factor: 5.250

5.  The real-world impact of dosing of methadone and buprenorphine in retention on opioid agonist therapies in Ukraine.

Authors:  Scott O Farnum; Iuliia Makarenko; Lynn Madden; Alyona Mazhnaya; Ruthanne Marcus; Tanya Prokhorova; Martha J Bojko; Julia Rozanova; Sergii Dvoriak; Zahedsul Islam; Frederick L Altice
Journal:  Addiction       Date:  2020-08-09       Impact factor: 6.526

6.  Act Healthy: A Randomized Clinical Trial Evaluating a Behavioral Activation Intervention to Address Substance Use and Medication Adherence Among Low-Income, Black/African American Individuals Living with HIV/AIDS.

Authors:  Jessica F Magidson; Jennifer M Belus; C J Seitz-Brown; Hannah Tralka; Steven A Safren; Stacey B Daughters
Journal:  AIDS Behav       Date:  2021-06-26

7.  Implementation of a Medication for Addiction Treatment (MAT) and Linkage Program by Leveraging Community Partnerships and Medical Toxicology Expertise.

Authors:  Gillian A Beauchamp; Lexis T Laubach; Samantha B Esposito; Ali Yazdanyar; Paige Roth; Priyanka Lauber; Jamie Allen; Nathan Boateng; Samantha Shaak; David B Burmeister
Journal:  J Med Toxicol       Date:  2020-11-04

8.  Tailoring services in opioid treatment programs for patients involved in America's criminal justice system: national associations and variation by state and Medicaid expansion status.

Authors:  George Pro; Brooke E E Montgomery; Nickolas Zaller
Journal:  Subst Abuse Treat Prev Policy       Date:  2021-06-19

Review 9.  A review of sleep disturbance in adults prescribed medications for opioid use disorder: potential treatment targets for a highly prevalent, chronic problem.

Authors:  Allison K Wilkerson; Aimee L McRae-Clark
Journal:  Sleep Med       Date:  2021-05-27       Impact factor: 4.842

10.  The association of prefrontal cortex response during a natural reward cue-reactivity paradigm, anhedonia, and demoralization in persons maintained on methadone.

Authors:  Andrew S Huhn; Robert K Brooner; Mary M Sweeney; Denis Antoine; Alexis S Hammond; Hasan Ayaz; Kelly E Dunn
Journal:  Addict Behav       Date:  2020-09-28       Impact factor: 3.913

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.